
Cytophage Technologies Ltd. — Investor Relations & Filings
Cytophage Technologies Ltd. is a pioneering biotechnology company focused on developing synthetic bacteriophage products to prevent and treat bacterial infections, aiming to reduce and ultimately replace the use of conventional antibiotics. The company utilizes molecular genetic techniques and proprietary synthetic biology technology to create tailor-made, highly effective phages that are harmless to humans and animals. Cytophage's solutions address three primary markets: Animal Health (e.g., livestock illness prevention and growth enhancement), Food Safety (preventing disease spread without antibiotics), and Human Health (treating bacterial illnesses and hospital decontamination). A key competitive advantage is the rapid production timeline for targeted phages, enabling quick response to bacterial threats. The company is also engaged in advanced research, including the development of genetically engineered phage-based vaccines.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| News release - English.pdf | 2026-04-15 | English | |
| News release - English.pdf | 2026-04-15 | English | |
| News release - English.pdf | 2026-04-15 | English | |
| News release - English.pdf | 2026-04-15 | English | |
| Report of exempt distribution (45-106F1).pdf | 2025-12-08 | English | |
| News release - English.pdf | 2025-11-29 | English |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
4 filings
| |||||
| 34546772 | News release - English.pdf | 2026-04-15 | English | ||
| 34543854 | News release - English.pdf | 2026-04-15 | English | ||
| 34538131 | News release - English.pdf | 2026-04-15 | English | ||
| 34534051 | News release - English.pdf | 2026-04-15 | English | ||
|
2025
11 filings
| |||||
| 32366236 | Report of exempt distribution (45-106F1).pdf | 2025-12-08 | English | ||
| 32363854 | News release - English.pdf | 2025-11-29 | English | ||
| 32352508 | News release - English.pdf | 2025-11-05 | English | ||
| 32344908 | News release - English.pdf | 2025-10-16 | English | ||
| 32315686 | Report of exempt distribution (45-106F1) (amended).pdf | 2025-09-15 | English | ||
| 32261461 | News release - English.pdf | 2025-07-28 | English | ||
| 13802110 | Report of exempt distribution (45-106F1).pdf | 2025-06-19 | English | ||
| 13800113 | News release - English.pdf | 2025-06-11 | French | ||
| 13796113 | News release - English.pdf | 2025-05-30 | English | ||
| 13796136 | Interim MD&A - English.pdf | 2025-05-30 | English | ||
| 13796135 | 52-109FV2 - Certification of interim filings - CFO (E).pdf | 2025-05-30 | English | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
AnorMED Inc.
Developed small molecule therapeutics for serious diseases,…
|
— | CA | Professional, scientific and te… |
|
ANTEOTECH LTD
Develops nanoglue technology for life sciences and lithium-…
|
ADO | AU | Professional, scientific and te… |
|
Anthem Biosciences Limited
Integrated CRAMS organization for drug discovery, developme…
|
ANTHEM | IN | Professional, scientific and te… |
|
APPLIED DNA SCIENCES INC
Develops and manufactures DNA-based technologies for geneti…
|
APDN | US | Professional, scientific and te… |
|
Aprea Therapeutics, Inc.
Clinical-stage biopharma developing cancer therapeutics via…
|
APRE | US | Professional, scientific and te… |
|
AprilBio Co.,Ltd.
Develops long-acting biologic drugs for autoimmune diseases…
|
397030 | KR | Professional, scientific and te… |
|
Aptahem AB
A clinical-stage biotech developing aptamer-based drugs for…
|
APTA | SE | Professional, scientific and te… |
|
APTAMER GROUP PLC
Develops custom affinity binders for research, diagnostics,…
|
APTA | GB | Professional, scientific and te… |
|
Aptevo Therapeutics Inc.
Clinical-stage biotech developing antibody-based immunother…
|
APVO | US | Professional, scientific and te… |
|
Aptose Biosciences Inc.
Clinical-stage company developing targeted precision medici…
|
APS | CA | Professional, scientific and te… |
Cytophage Technologies Ltd. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/48283/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=48283 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=48283 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=48283 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 48283}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Cytophage Technologies Ltd. (id: 48283)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.